Determining the prognostic significance of IKKα in prostate cancer

Melania Montes PhD1 | Lewis MacKenzie PhD2 | Milly J. McAllister PhD1 | Antonia Roseweir PhD1,3 | Pamela McCall PhD1 | Sophia Hatziieremia PhD1 | Mark A. Underwood MD4 | Marie Boyd PhD2 | Andrew Paul PhD2 | Robin Plevin PhD2 | Simon P. MacKay PhD2 | Joanne Edwards PhD1

1Unit of Gastrointestinal and Molecular Pathology, Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, Institute of Cancer Science, University of Glasgow, Glasgow, UK
2Strathclyde Institute of Pharmacy and Biomedical Sciences, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK
3Academic Unit of Surgery, School of Medicine, University of Glasgow, Glasgow, UK
4Department of Urology, Queen Elizabeth University Hospital, Glasgow, UK

Correspondence
Melania Montes, PhD, Unit of Experimental Therapeutics, Institute of Cancer Science, University of Glasgow, Glasgow G61 1qh, United Kingdom.
Email: melaniamontes14@gmail.com

Abstract

Background: As the survival of castration-resistant prostate cancer (CRPC) remains poor, and the nuclear factor-xB (NF-xB) pathways play key roles in prostate cancer (PC) progression, several studies have focused on inhibiting the NF-xB pathway through generating inhibitory xB kinase subunit α (IKKα) small molecule inhibitors. However, the identification of prognostic markers able to discriminate which patients could benefit from IKKα inhibitors is urgently required. The present study investigated the prognostic value of IKKα, IKKα phosphorylated at serine 180 (p-IKKα S180) and threonine 23 (p-IKKα T23), and their relationship with the androgen receptor (AR) and Ki67 proliferation index to predict patient outcome.

Methods: A cohort of 115 patients with hormone-naïve PC (HNPC) and CRPC specimens available were used to assess tumor cell expression of proteins within both the cytoplasm and the nucleus by immunohistochemistry. The expression levels were dichotomized (low vs high) to determine the associations between IKKα, AR, Ki67, and patients’ survival. In addition, an analysis was performed to assess potential IKKα associations with clinicopathological and inflammatory features, and potential IKKα correlations with other cancer pathways essential for CRPC growth.

Results: High levels of cytoplasmic IKKα were associated with a higher cancer-specific survival in HNPC patients with low AR expression (hazards ratio [HR], 0.33; 95% confidence interval [CI] log-rank, 0.11-0.98; P = .04). Furthermore, nuclear IKKα (HR, 2.60; 95% CI, 1.27-5.33; P = .01) and cytoplasmic p-IKKα S180 (HR, 2.10; 95% CI, 1.17-3.76; P = .01) were associated with a lower time to death from recurrence in patients with CRPC. In addition, high IKKα expression was associated with high levels of T-cells (CD3+ P = .01 and CD8+ P = .03) in HNPC; however, under castration conditions, high IKKα expression was associated with high levels of CD68+ macrophages (P = .04), higher Gleason score (P = .01) and more prostate-specific antigen concentration (P = .03). Finally, we identified crosstalk between IKKα and

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2020 The Authors. The Prostate published by Wiley Periodicals LLC
members of the canonical NF-κB pathway in the nucleus of HNPC. Otherwise, IKKα phosphorylated by noncanonical NF-κB and Akt pathways correlated with members of the canonical NF-κB pathway in CRPC.

Conclusion: The present study reports that patients with CRPC expressing high levels of nuclear IKKα or cytoplasmic p-IKKα S180, which associated with a lower time to death from recurrence, may benefit from IKKα inhibitors.

KEYWORDS
androgen receptor, castration-resistant prostate cancer, noncanonical NF-κB pathway

1 | INTRODUCTION

Prostate cancer (PC) remains the most commonly diagnosed noncutaneous malignancy in men and the second most common cause of cancer death worldwide. Active surveillance, radical prostatectomy, brachytherapy, and external beam radiotherapy are currently the most common treatments for localized PC. However, androgen deprivation therapy (ADT) and/or chemotherapies are the most indicated remedy to treat advanced or metastatic PC. Ninety percent of patients have remission of the disease, which always develops into castration-resistant prostate cancer (CRPC) within 2 to 3 years. Metastatic CRPC associates with poor prognosis and the mean survival time is approximately 18 months. As androgen receptor (AR) signaling is the main driver of PC cell proliferation and survival, understanding ADT resistance mechanisms and new adjuvant therapies are required to improve patient survival. Some of these mechanisms have been explained during the last few years. As prostate cells are androgen-dependent, the absence of androgens leads to apoptotic cell death, which promotes inflammation surrounding the tumor, which is related to the constitutive activation of the nuclear factor kappa-light-chain-enhancer of the activated B cell (nuclear factor-κB [NF-κB]) pathway. The NF-KB family comprises five proteins- RelA/p65, NFKB1/p50, c-Rel, RelB, and NF-xB 2/p52. In absence of stimulus, these proteins reside in the cytoplasm forming homo- or heterodimers and typically are bound to an inhibitory protein (inhibitor of KBs). Under the stimulus, NF-xBs are activated via one of two cascades (canonical and noncanonical). Briefly, canonical NF-xB signaling is activated by the cytoplasmic inhibitory x-B kinase (IKK) complex composed of IKK subunits α and β (IKKα and IKKβ) and the regulatory subunit NF-xB essential modulator (NEMO or IKKγ). Upon stimulation, the IKK complex catalyzes the phosphorylation of IKBα in a manner that is dependent on IKKβ. This results in the targeted degradation of IKBα and the release of the p65-p50 dimer to accumulate in the nucleus. On the other hand, IKKα homodimers and nuclear factor KB-inducing kinase (NIK) are the main drivers for the activation of the noncanonical NF-xB pathway. Following their activation, the RelB-p100 heterodimer is processed to RelB-p52. The upregulation of the noncanonical NF-xB subunit p52 has been described as important in PC. For example, Lessard et al reported RelB-p52 dimers are more expressed in PC cores than the canonical NF-xB subunits RelA and p50.

In addition, the number of nuclear RelB-positive cores was correlated with higher Gleason scores, suggesting the role of noncanonical NF-κB subunits in the progression of PC. Furthermore, they reported that androgenic stimulation of LNCaP cells (androgen-sensitive cells) with the androgen analog R1881 positively regulates the noncanonical NF-κB pathway as p52 accumulates both in the nucleus and the cytoplasm. Hence, Nadimity et al demonstrated that the overexpression of the p52 subunit was implicated in castration-resistant growth by inhibiting LNCaP cell cycle arrest and apoptosis in the androgen-deprived condition in vitro and inducing LNCaP cell growth in castrated nude mice in vivo. Furthermore, this was accompanied by continued expression and activation of the AR, providing evidence that p52 may activate AR during CRPC development. Subsequently, Nadimity et al exhibited that RelB-p52 with AR gene coactivators induce the aberrant activation of AR. In addition, they proved that the knockdown of p52 reduce AR activity in LNCaP cells. Furthermore, they showed that several genes involved in cell growth, proliferation, and movement were potential targets of RelB/p52. Collectively, these findings suggest a role for RelB/p52 in the progression of CRPC. More importantly, the resistance to next-generation anti-androgens (enzalutamide) was associated with AR and AR splice variants activation derived from an increase of RelB/p52 expression. Targeting the noncanonical NF-κB pathway could, therefore, offer a new treatment paradigm for PC in combination with ADT.

NIK and IKKα are current therapeutic targets under investigation in the noncanonical NF-κB pathway due to their crucial role in processing p100 to p52. In PC, IKKα-focused studies emphasized its function in controlling invasiveness, metastasis and inflammation, suggesting the therapeutic potential of IKKα inhibition. For example, IKKα inhibition by using synthetic small interference RNAs confirmed its major role in PC invasion and metastasis. In addition, a few studies implicate IKKα in cancer cell proliferation. Karin et al determined epithelial proliferation being regulated by IKKα, although this study was on breast cancer (BCa). In PC, Shukla et al examined the effect of inhibiting IKKα kinase by using apigenin and demonstrated antiproliferative and anti-inflammatory effects.

Despite many reports in the literature describing the development of IKKα inhibitors (subsequently abandoned because of reports of target-related toxicity), potent and selective IKKα inhibitors with in vivo activity remain unknown. Although we have made some
progress in this respect and a IKKα clinical candidate(s) should emerge from our work, the discovery of prognostic markers able to identify which patients could benefit from this therapy is urgently required. Previously, we have demonstrated that high IKKα expression was associated with reduced time to recurrence (TTR) and cancer specific survival (CSS) in estrogen receptor positive BCa. This study aims to assess whether combining IKKα expression and stratification of patients according to their AR status can predict those likely to respond to combination therapy of ADT and an IKKα inhibitor. Furthermore, since as little is known about the involvement of IKKα in PC cell proliferation, and its function has been seen more related to invasive and metastatic capacities, we assessed the association between proliferative index Ki67 and IKKα as well as its prognostic value during the progression to CRPC.

2 MATERIALS AND METHODS

2.1 Patient cohort and sample collection

A total of 115 patients were included in this study, diagnosed between 1984 to 2000 at the Edinburgh Western General Hospital, Glasgow Royal Infirmary Hospital and Kilmainnock Crosshouse Hospital. Patients who initially responded to androgen ablation treatment (sub-capsular bilateral orchidectomy or LHRH agonists combined with anti-androgens) and subsequently relapsed (two consecutive rises in prostate-specific antigen [PSA] >10%) were included in the study. All selected patients had both hormone-naïve PC (HNPC) specimens gathered via trans-rectal ultrasound guided biopsies and CRPC specimens gathered via transurethral resection of the prostate to relieve bladder outflow obstruction available. Information relating to clinical diagnosis, treatment and outcome was obtained from the pathology notes including age (median 70 years, interquartile range (IQR), 66-74), PSA at diagnosis (median, 34.5 ng/mL; IQR, 9-126), PSA at recurrence (median 16 ng/mL; IQR, 5-39), Gleason score at diagnosis (median score 7.5; IQR, 6-9), Gleason score at recurrence (median score 9; IQR, 8-9), time to recurrence (median 2.6 years; IQR, 1.6-4.3), time to death from relapse (TTDR median 2.2 years. IQR 1.0-3.6) and CSS (median 5.5 years; IQR, 3.4-7.3). The study was approved by the Multicentre Research Ethics Committee from Scotland (MREC/01/0/36) and Local Research and Ethical Committees.

2.2 Immunohistochemistry

IHC was performed on 4 μm sections to assess total IKKα, IKKα phosphorylated at serine 180 (p-IKKα S180) and threonine 23 (p-IKKα T23). IHC for IKKβ, NEMO, Akt phosphorylated at the serine 473 (p-Akt S473), Ki67 and AR had previously been performed in this cohort. Slides were deparaffinised with xylene and rehydrated through a series of graded alcohols. Heat-induced antigen retrieval was performed using citrate buffer pH 6 (Vector Laboratories, CA) under pressure for 5 minutes. Endogenous peroxidase activity was blocked using 3% (vol/vol) hydrogen peroxide and nonspecific background staining was blocked using 5% (vol/vol) horse serum in Tris-buffered saline for 20 minutes. Total IKKα (Cat GWB-662250; Genway), p-IKKα S180 (Cat ab138426; Abcam) and p-IKKα T23 (Cat ab38515; Abcam) primary antibodies were used. Slides were then incubated in these primary antibodies overnight at 4°C; with the following antibody concentrations: total IKKα at 1:1000, p-IKKα S180 at 1:200, and p-IKKα T23 at 1:200. Envision (Dako) was added to the sections for 30 minutes at room temperature then slides were dehydrated and mounted using a distrene, plasticizer, xylene.

2.3 Scoring method

Stained sections were scanned using a Hamamatsu NanoZoomer (Welwyn Garden City, Hertfordshire, UK) at ×20 magnification, and visualization was carried out using Slidepath Digital Image Hub, version 4.0.1 (Slidepath, Leica Biosystems, Milton Keynes, UK). Cytoplasmic and nuclear protein staining were assessed separately. Slides were scored by two independent observers using the weighted histoscore method, and the interclass correlation coefficient was greater than 0.7 for all antibodies. If a difference of more than 50 weighted histoscore units was observed, the core was re-scored by both observers independently, in the majority of the cases this resolved any differences in scores, however, if there still remained a difference, both observers discussed the case and reached a consensus. The weighted histoscore is calculated using the following equation: $0 \times (%\text{ cells not stained}) + 1 \times (%\text{ cells weakly stained}) + 2 \times (%\text{ cells moderately stained}) + 3 \times (%\text{ cells strongly stained})$. This gives a range of scores from 0 to 300. Ki67 was assessed using a point count and <1% considered high expression.

2.4 Assessment of the local inflammatory infiltration

The number of T-lymphocytes (CD3+, CD8+, and FOXP3+) and macrophages (CD68+) was determined by IHC for this cohort using the following antibodies: CD3 (Cat RM-9107-S, 1:1000; Thermo Fisher Scientific), CD8 (Cat Clone C8/114B, 1:200; Dako), FOXP3 (Cab22510, 1:100; Abcam) and CD68 (Cat M0876, 1:200; Dako). Briefly, the density for each immune cell subtype was evaluated and the immune infiltration was graded as absent, weak, moderate or strong using a semi-quantitative method.

2.5 Statistical analysis

Statistics were performed using the SPSS version 25.0 (IBM, Armonk, NY) and P values of less than .05 were considered statistically significant. Cut-off values to dichotomize each protein into low and high expression were determined using receiver operating characteristic
We investigated the associations between AR, Ki67, total IKKα, p-IKKα S180, p-IKKα T23 and TTR, TTDR, or CSS during the transition from HNPC to CRPC (Table 2). Ki67 proliferation rate and CSS were associated at the time of diagnosis (HR, 2.5; 95% CI, 1.2-5.0; P = .01); patients with HNPC presenting high Ki67 expression were associated with significantly shorter CSS. However, following transition to CRPC, high Ki67 expression was associated with shorter TTDR (HR, 2.6; 95% CI, 1.3-5.2; P = .01) with patients with a high Ki67 having a reduced 2-year TTDR of 46% compared with 69% for those with low Ki67. In addition, high levels of cytoplasmic p-IKKα S180 (HR, 2.10; 95% CI, 1.17-3.76; P = .01) and nuclear IKKα (HR, 2.60; 95% CI, 1.27-5.33; P = .01) were associated with significantly shorter TTDR.

### Table 1: Overview of patients' characteristics (n = 115)

| Clinicopathological parameters | N (%) | Median (IQR) |
|-------------------------------|-------|--------------|
| Age (<70/>70/unknown)          | 55 (48)/10 (9)/48 (42)/2 (2) | 70 (66-74) |
| Gleason at diagnosis (<7/7/>7/unknown) | 28 (24)/24 (21)/52 (45)/11 (10) | 7.5 (6-9) |
| Gleason at recurrence (<7/7/>7/unknown) | 5 (4)/12 (10)/90 (78)/8 (7) | 9 (8-9) |
| PSA at diagnosis (<10 ng/mL/>10 ng/mL/unknown) | 29 (25)/69 (60)/17 (15) | 34.5 (9-126) |
| PSA at recurrence (<10 ng/mL/>10 ng/mL/unknown) | 26 (23)/32 (28)/57 (50) | 16 (5-39) |
| Ki67 at diagnosis (<1% cells/>1% cells/unknown) | 14 (12)/47 (41)/54 (47) | 3.0 (1.0-6.5) |
| Ki67 at recurrence (<1% cells/>1% cells/unknown) | 11 (10)/58 (50)/46 (40) | 8.0 (3.0-16.0) |

**Abbreviations:** IQR, interquartile range; PSA, prostate-specific antigen.

### RESULTS

#### 3.1 Patient characteristics

We analyzed 115 patients that progressed from HNPC to CRPC to investigate IKKα and AR as biomarkers for combination therapy (Table 1). Forty-eight percent of patients were younger than 70 years of age and 41% patients had a high proliferation rate for HNPC, and this increased to 50% with progression to CRPC. Similarly, for Gleason grade, 45% patients had a high tumor grade for HNPC, and this increased to 78% with progression to CRPC. Conversely, PSA concentration decreased during the transition to CRPC, 60% patients had a high PSA concentration for HNPC, and this decreased to 28% with progression to CRPC. Median follow-up was 4.9 years (IQR, 3.3-7.0) with 68 cancer and 40 non-cancer deaths. All patients presented biochemical relapse (TTR median 2.6 years; IQR, 1.6-4.3).

#### 3.2 The molecular prognostic profile differed between HNPC and CRPC

We investigated the associations between AR, Ki67, total IKKα, p-IKKα S180, p-IKKα T23 and TTR, TTDR, or CSS during the transition from HNPC to CRPC (Table 2). Ki67 proliferation rate and CSS were associated at the time of diagnosis (HR, 2.5; 95% CI, 1.2-5.0; P = .01).

As IKKα has a role in the transition from HNPC to CRPC by enhancing the expression of genes transcribed by AR, we stratified patients based on their AR protein expression. In HNPC, patients with high levels of cytoplasmic IKKα and low AR expression associated with greater CSS (HR, 0.33; 95% CI, 0.11-0.98; log-rank P = .04, Figure 1B). Conversely, cytoplasmic IKKα expression was not associated with survival in the full cohort (HR, 0.72; 95% CI, 0.36-1.43; log-rank P = .34; Figure 1A) or patients with high AR expression (HR, 3.37; 95% CI, 0.95-12.04; log-rank P = .05; Figure 1C). Furthermore, a lower expression of cytoplasmic IKKα was strongly associated with >10 ng/mL PSA in the full cohort (P ≤ .001) as shown in Table 3. In CRPC, no associations were seen in low or high AR expressed patients for cytoplasmic or nuclear IKKα (Table S2).

#### 3.4 Patient stratification based on their Ki67 proliferation rate enhanced the prognostic effect of IKKα phosphorylation at S180 and T23

As high proliferative index Ki67 is associated with poorer PC survival and IKKα suppression possesses an antiproliferative effect, we investigated the association of IKKα and patient outcome in patients stratified for low and high Ki67. In HNPC (Table S1), high cytoplasmic p-IKKα S180 associated with better CSS in patients with high Ki67 (HR, 0.8; 95% CI, 0.2-4.1; P = .02). No associations were seen for any...
TABLE 2 | Associations between androgen receptor, Ki67, total IKKα, p-IKKα S180, p-IKKα T23, and survival during the transition from hormone-naïve to castration-resistant prostate cancer (n = 115)

|                | Hormone-naïve prostate cancer | Castration-resistant prostate cancer |
|----------------|------------------------------|-----------------------------------|
|                | 2-y CSS (SE) | P | N (%) | 2-y TTR (SE) | P | N (%) | 2-y TTR (SE) | P |
| Androgen receptor |        |     |       |        |     |       |        |     |
| Low            | N (%) | 38 | .07   | 95 (0.04) | 36 | (54.5) | 64 (0.08) | 21 | (32) | 100 (0.00) | 19 | (30) | 71 (0.11) | .06 |
| High           | N (%) | 31 | .86   | 90 (0.06) | 30 | (45.5) | 60 (0.09) | 44 | (68) | 88 (0.05) | 44 | (70) | 42 (0.08) | .06 |
| Ki67           |        |     |       |        |     |       |        |     |
| Low            | N (%) | 27 | .01*  | 92 (0.05) | 27 | (46) | 63 (0.09) | 24 | (36) | 91 (0.06) | 24 | (36) | 69 (0.10) | .01* |
| High           | N (%) | 32 | .86   | 94 (0.04) | 32 | (54) | 59 (0.09) | 43 | (64) | 93 (0.04) | 42 | (64) | 46 (0.08) | .01* |
| cIKKα          |        |     |       |        |     |       |        |     |
| Low            | N (%) | 27 | .34   | 93 (0.05) | 25 | (52) | 68 (0.09) | 46 | (68) | 96 (0.03) | 44 | (67) | 66 (0.07) | .10 |
| High           | N (%) | 22 | .12   | 86 (0.07) | 23 | (48) | 65 (0.10) | 22 | (32) | 86 (0.07) | 22 | (33) | 48 (0.11) | .77 |
| nIKKα          |        |     |       |        |     |       |        |     |
| Low            | N (%) | 25 | .97   | 88 (0.07) | 23 | (48) | 65 (0.10) | 21 | (31) | 90 (0.07) | 21 | (32) | 73 (0.10) | .01* |
| High           | N (%) | 24 | .34   | 92 (0.06) | 25 | (52) | 68 (0.09) | 47 | (69) | 94 (0.04) | 45 | (68) | 54 (0.08) | .01* |
| c p-IKKα S180  |        |     |       |        |     |       |        |     |
| Low            | N (%) | 9  | .60   | 100 (0.00) | 9  | (17) | 67 (0.16) | 39 | (59) | 97 (0.03) | 37 | (58) | 74 (0.08) | .01* |
| High           | N (%) | 44 | .06   | 83 (0.04) | 43 | (83) | 70 (0.07) | 27 | (41) | 89 (0.06) | 27 | (42) | 40 (0.10) | .07 |
| n p-IKKα S180  |        |     |       |        |     |       |        |     |
| Low            | N (%) | 27 | .86   | 93 (0.05) | 26 | (50) | 69 (0.09) | 33 | (50) | 94 (0.04) | 32 | (50) | 67 (0.09) | .51 |
| High           | N (%) | 26 | .83   | 92 (0.05) | 26 | (50) | 69 (0.09) | 33 | (50) | 94 (0.04) | 32 | (50) | 51 (0.09) | .56 |
| c p-IKKα T23   |        |     |       |        |     |       |        |     |
| Low            | N (%) | 29 | .99   | 93 (0.05) | 27 | (51) | 74 (0.08) | 38 | (54) | 95 (0.04) | 37 | (54) | 57 (0.08) | .85 |
| High           | N (%) | 25 | .67   | 92 (0.05) | 26 | (49) | 73 (0.09) | 32 | (46) | 94 (0.04) | 31 | (46) | 62 (0.09) | .31 |
| n p-IKKα T23   |        |     |       |        |     |       |        |     |
| Low            | N (%) | 27 | .59   | 96 (0.04) | 27 | (51) | 74 (0.08) | 35 | (50) | 97 (0.03) | 33 | (48.5) | 66 (0.09) | .75 |
| High           | N (%) | 27 | .77   | 89 (0.06) | 26 | (49) | 73 (0.09) | 35 | (50) | 91 (0.05) | 35 | (51.5) | 54 (0.08) | .63 |

Abbreviations: c/n, cytoplasmic/nuclear; CSS, cancer specific survival; IKK, inhibitory κ-B kinase; IKKα, IKK subunits α; TTR, time to death from relapse; TTR, time to recurrence. *P ≤ .01.

...other markers in patients with HNPC. In CRPC (Table S2), high expression of nuclear p-IKKα T23 was associated with better CSS (HR, 0.1; 95% CI, 0.01-0.8; P = .007; Figure 2B) and greater TTDR (HR, 0.1; 95% CI, 0.02-1.3; P = .04; Figure 3B) in patients expressing low Ki67. However, no significant associations were seen for the full cohort (Figures 2A and 3A) or patients with high Ki67 (Figures 2C and 3C). No associations were seen for any other markers for CRPC.

3.5 | IKKα associated with markers of adaptive immunity in HNPC but innate immunity in CRPC

As IKKα is involved in PC progression and CRPC growth due to interactions with inflammatory modulators and AR signaling, we investigated associations between total IKKα, p-IKKα S180 or p-IKKα T23, and clinicopathological parameters and inflammatory regulators (Table 3). For HNPC, low total cytoplasmic IKKα associated with increased PSA levels (P = .001), and high cytoplasmic p-IKKα T23 associated with a strong CD3+ (P = .01) and CD8+ (P = .03) lymphocytic infiltration. No associations where seen for nuclear expression. For CRPC, high total cytoplasmic IKKα was associated with strong CD68+ macrophage infiltration (P = .04) whereas high cytoplasmic p-IKKα T23 associated with weak CD3+ lymphocytic infiltration (P = .04). Finally, high nuclear p-IKKα T23 associated with increased Gleason score (P = .01), and high nuclear p-IKKα S180 associated with increased PSA levels (P = .03). No associations were seen for total nuclear IKKα.

3.6 | IKKα was correlated with members of the canonical NF-κB, PI3/Akt, and AR pathways

As IKKα has been previously seen to interact with members of other cancer pathways involved in CRPC growth, such as the canonical NF-κB, PI3/AKT, and AR pathways, we evaluated potential correlations between total IKKα, p-IKKα S180, and p-IKKα T23, and some of the members of these pathways (Table 4). Total IKKα correlated with NEMO (P = .04), and p-IKKα T23 correlated with AR (P = .02) in the nucleus of HNPC cells. Otherwise, total IKKα, p-IKKα
Cytoplasmic IKKα in hormone-naïve PC
Low
High
HR 0.72 95% CI 0.36-1.43 log-rank p=0.34

Low androgen receptor and cytoplasmic IKKα in hormone-naïve PC
Low
High
HR 0.33 95% CI 0.11-0.98 log-rank p=0.04

High androgen receptor and cytoplasmic IKKα in hormone-naïve PC
Low
High
HR 3.37 95% CI 0.95-12.04 log-rank p=0.05

**FIGURE 1** Cytoplasmic inhibitory κ-B kinase subunits α (IKKα) associated with good prognosis in high AR-expressed patients with hormone-naïve prostate cancer (HNPC). Kaplan-Meier plots showing associations between cancer specific survival (CSS) and (A) cytoplasmic IKKα expression. B, C. Kaplan-Meier curves showing associations between CSS and cytoplasmic IKKα in (B) low and (C) high patients with androgen receptor (AR). CI, confidence interval; HR, hazards ratio.
### Table 3: The relationship between total IKKα, p-IKKα S180, p-IKKα T23, clinicopathological parameters and inflammatory features during the transition from hormone-naive to castration-resistant prostate cancer (n = 115)

|                  | IKKα          | p-IKKα S180 | p-IKKα T23 |
|------------------|---------------|-------------|------------|
|                  | Cytoplasmic   | Nuclear     | Cytoplasmic| Nuclear    | Cytoplasmic| Nuclear    |
|                  | Low (%)       | High (%)    | P          | Low (%)    | High (%)    | P          | Low (%)    | High (%)    | P          | Low (%)    | High (%)    | P          |
| Hormone-naive prostate cancer |
| Clinicopathological parameters |
| Age, years       | .18           | .05         | .18        | .78        | .05         | .27        |
| ≤70              | 18 (67)       | 11 (48)     |            | 7 (78)     | 24 (53)     |            | 16 (59)    | 15 (56)     |            | 14 (48)    | 20 (74)     |            |
| >70              | 9 (33)        | 12 (52)     |            | 7 (28)     | 14 (56)     |            | 2 (22)     | 21 (47)     |            | 11 (41)    | 12 (44)     |            |
| Gleason score    | .93           | .05         | .39        | .26        | .99         | .95        |
| <7               | 7 (26)        | 5 (22)      |            | 4 (44)     | 10 (23)     |            | 6 (23)     | 8 (30)      |            | 9 (31)     | 8 (30)      |            |
| >7               | 6 (22)        | 5 (22)      |            | 2 (8)      | 8 (32)      |            | 1 (11)     | 9 (21)      |            | 3 (12)     | 7 (26)      |            |
| PSA, ng/mL       | .001***       | .62         | .05        | .38        | .67         | .80        |
| ≤10              | 2 (8)         | 10 (50)     |            | 0 (0)      | 13 (31)     |            | 5 (20)     | 8 (31)      |            | 7 (25)     | 7 (30)      |            |
| >10              | 24 (92)       | 10 (50)     |            | 17 (77)    | 17 (71)     |            | 9 (100)    | 29 (69)     |            | 20 (80)    | 18 (69)     |            |
| Ki67             | .72           | .16         | .13        | .27        | .24         | .31        |
| ≤1% cells        | 6 (35)        | 7 (41)      |            | 4 (67)     | 10 (33)     |            | 9 (47)     | 5 (29)      |            | 6 (29)     | 8 (47)      |            |
| >1% cells        | 11 (65)       | 10 (59)     |            | 7 (50)     | 14 (74)     |            | 2 (33)     | 20 (67)     |            | 10 (53)    | 12 (71)     |            |
| Inflammatory features |
| CD68+ macrophages| .31           | .41         | .41        | .08        | .43         | .51        |
| Low              | 3 (33)        | 2 (67)      |            | 1 (25)     | 4 (50)      |            | 1 (25)     | 4 (50)      |            | 1 (17)     | 4 (67)      |            |
| High             | 6 (67)        | 1 (33)      |            | 3 (75)     | 4 (50)      |            | 3 (75)     | 4 (50)      |            | 5 (83)     | 2 (33)      |            |
| CD8+ T-cells     | .62           | .74         | .30        | .74        | .003*       | .62        |
| Low              | 4 (50)        | 2 (67)      |            | 3 (60)     | 3 (50)      |            | 3 (75)     | 3 (43)      |            | 6 (75)     | 0 (0)       |            |
| High             | 4 (50)        | 1 (33)      |            | 2 (40)     | 3 (50)      |            | 1 (25)     | 4 (57)      |            | 2 (40)     | 3 (50)      |            |
| CD3+ T-cells     | .89           | .62         | .82        | .01**      | .09         | .87        |
| Low              | 5 (56)        | 1 (50)      |            | 2 (67)     | 4 (50)      |            | 2 (67)     | 4 (57)      |            | 6 (86)     | 0 (0)       |            |
| High             | 4 (44)        | 1 (50)      |            | 1 (33)     | 4 (50)      |            | 1 (33)     | 4 (50)      |            | 1 (14)     | 4 (100)     |            |
| FOXP3+ T-cells   | .24           | .09         | .85        | .80        | .09         | .87        |
| Low              | 4 (40)        | 3 (75)      |            | 1 (20)     | 6 (67)      |            | 2 (50)     | 5 (56)      |            | 3 (50)     | 4 (57)      |            |
| High             | 6 (60)        | 1 (25)      |            | 4 (80)     | 33 (9)      |            | 2 (50)     | 4 (44)      |            | 3 (50)     | 3 (43)      |            |
### TABLE 3 (Continued)

|                  | IKKα   |             | p-IKKα S180 |             | p-IKKα T23 |
|------------------|--------|-------------|-------------|-------------|------------|
|                  | Cytoplasmic | Nuclear       | Cytoplasmic | Nuclear       | Cytoplasmic | Nuclear       |
|                  | Low (%) | High (%) | P | Low (%) | High (%) | P | Low (%) | High (%) | P | Low (%) | High (%) | P | Low (%) | High (%) | P |
| Castration-resistant prostate cancer |        |             |             |             |            |             |             |             |             |            |             |             |             |             |             |
| Clinicopathological parameters |        |             |             |             |            |             |             |             |             |            |             |             |             |             |             |
| Age, years       | .30    | .65        | .10         | .70         | .27        | .47         |             |             |             |             |             |             |             |             |             |
| ≤70              | 24 (52) | 15 (65)    |             | 26 (67)    | 13 (46)    |             | 19 (56)    | 20 (61)    |             | 25 (66)    | 18 (53)    |             | 23 (64)    | 20 (56)    |             |
| >70              | 22 (48) | 8 (35)     |             | 13 (33)    | 15 (54)    |             | 15 (44)    | 13 (39)    |             | 13 (34)    | 16 (47)    |             | 13 (36)    | 16 (44)    |             |
| Gleason score    | .96    | .50        | .13         | .51         | .43        | .01**      |             |             |             |             |             |             |             |             |             |
| ≤7              | 2 (5)   | 1 (5)      |             | 1 (3)      | 1 (3)      |             | 1 (3)      | 3 (9)      |             | 3 (9)      | 1 (3)      |             |             |             |             |
| >7              | 5 (11)  | 2 (9)      |             | 5 (15)     | 2 (6)      |             | 4 (11)     | 2 (6)      |             | 6 (18)     | 0 (0)      |             |             |             |             |
| PSA, ng/mL       | .46    | .43        | .28         | .03*       | .66        | .90         |             |             |             |             |             |             |             |             |             |
| ≤10             | 16 (52) | 6 (40)     |             | 14 (61)    | 7 (29)     |             | 10 (42)    | 12 (48)    |             | 11 (46)    | 11 (44)    |             |             |             |             |
| >1              | 15 (48) | 9 (60)     |             | 9 (39)     | 17 (71)    |             | 14 (58)    | 13 (52)    |             | 13 (54)    | 14 (56)    |             |             |             |             |
| Ki67             | .67    | .15        | .74         | .74         | .53        | .67         |             |             |             |             |             |             |             |             |             |
| ≤1% cells        | 8 (31)  | 7 (37)     |             | 7 (32)     | 6 (27)     |             | 6 (38)     | 7 (29)     |             | 7 (37)     | 8 (31)     |             |             |             |             |
| >1% cells        | 18 (69) | 12 (63)    |             | 15 (68)    | 16 (73)    |             | 13 (62)    | 17 (71)    |             | 12 (63)    | 18 (69)    |             |             |             |             |
| Inflammatory features |      |             |             |             |            |             |             |             |             |             |             |             |             |             |             |
| CD68+ macrophages | .04*   | .33        | .49         | .76         | .33        | .64         |             |             |             |             |             |             |             |             |             |
| Low              | 5 (56)  | 0 (0)      |             | 4 (33)     | 0 (0)      |             | 3 (33)     | 1 (25)     |             | 3 (33)     | 3 (60)     |             | 3 (38)     | 3 (50)     |             |
| High             | 4 (44)  | 5 (100)    |             | 8 (67)     | 1 (100)    |             | 6 (67)     | 3 (75)     |             | 6 (67)     | 2 (40)     |             | 5 (63)     | 3 (50)     |             |
| CD8+ T-cells     | .41    | .08        | .43         | .55         | .56        | .92         |             |             |             |             |             |             |             |             |             |
| Low              | 4 (50)  | 3 (75)     |             | 6 (60)     | 1 (100)    |             | 4 (67)     | 3 (75)     |             | 4 (67)     | 3 (50)     |             | 4 (57)     | 3 (60)     |             |
| High             | 4 (50)  | 1 (25)     |             | 3 (43)     | 1 (25)     |             | 2 (33)     | 3 (50)     |             | 2 (33)     | 3 (50)     |             | 3 (43)     | 2 (40)     |             |
| CD3+ T-cells     | .20    | .53        | .19         | .51         | .04*       | .12         |             |             |             |             |             |             |             |             |             |
| Low              | 5 (56)  | 1 (20)     |             | 4 (44)     | 1 (25)     |             | 2 (22)     | 4 (80)     |             | 2 (25)     | 4 (67)     |             |             |             |             |
| High             | 4 (44)  | 4 (80)     |             | 5 (56)     | 3 (75)     |             | 7 (78)     | 1 (20)     |             | 6 (75)     | 2 (33)     |             |             |             |             |
| FOXP3+ T-cells   | .46    | .78        | .37         | .20         | .46        | .45         |             |             |             |             |             |             |             |             |             |
| Low              | 6 (60)  | 2 (40)     |             | 7 (54)     | 1 (100)    |             | 4 (44)     | 4 (80)     |             | 6 (60)     | 2 (40)     |             | 5 (63)     | 3 (43)     |             |
| High             | 4 (40)  | 3 (60)     |             | 6 (46)     | 0 (0)      |             | 5 (56)     | 1 (20)     |             | 4 (40)     | 3 (60)     |             | 3 (38)     | 4 (57)     |             |

Abbreviations: IKK, inhibitory κ-B kinase; IKKα, IKK subunits α; PSA, prostate-specific antigen.

*P < .05; **P ≤ .01; ***P ≤ .001.
FIGURE 2 Nuclear p-IKKα T23 is associated with good prognosis in castration-resistant prostate cancer (CRPC) patients with low Ki67. A, Kaplan Meier curves showing associations of nuclear p-IKKα T23 and CSS in the full cohort. B, Kaplan Meier curves showing associations of nuclear p-IKKα T23 and CSS in patients with low Ki67. C, Kaplan Meier curves showing associations of nuclear p-IKKα T23 and CSS in patients with high Ki67.

Number of patients at risk:
(A) Low 35(0) 34(0) 21(4) 9(8) 4(10) 2(11)
   High 55(0) 32(0) 26(0) 21(1) 8(6) 4(6)

Low Ki67 and nuclear p-IKKα T23 in castration-resistant PC
HR 0.9 95% CI 0.5-1.5 log-rank p=0.63

Number of patients at risk:
(B) Low 6(0) 5(0) 1(1) 0(2) 0(2) 0(2)
   High 8(0) 8(0) 8(0) 6(1) 3(3) 2(3)

High Ki67 and nuclear p-IKKα T23 in castration-naive PC
HR 1.0 95% CI 0.4-2.2 log-rank p=0.93

Number of patients at risk:
(C) Low 12(0) 12(0) 7(1) 3(2) 1(3) 0(3)
   High 17(0) 14(0) 11(0) 9(0) 1(1) 0(1)

CI, confidence interval; CRPC, castration-resistant prostate cancer; CSS, cancer specific survival; HR, hazards ratio; IKK, inhibitory κ-B kinase; IKKα, IKK subunits α.
Nuclear p-IKKα T23 is associated with good prognosis in CRPC patients with low Ki67.

(A) Kaplan Meier curves showing associations of nuclear p-IKKα T23 and time to death from relapse (TTDR) in the full cohort.

Number of patients at risk:
- Low: 33(0) 17(1) 4(1) 2(1) 1(1) 0(1)
- High: 35(0) 18(1) 6(8) 1(8) 0(8)

Low Ki67 and nuclear p-IKKα T23 in castration-resistant PC
- Low
- High
- HR 0.1 95% CI 0.02-1.3 log-rank p=0.04

(B) Kaplan Meier curves showing associations of nuclear p-IKKα T23 and TTDR in patients with low Ki67.

Number of patients at risk:
- Low: 6(0) 1(1) 0(2) 0(2) 0(2) 0(2)
- High: 8(0) 6(1) 1(4) 0(5) 0(5) 0(5)

High Ki67 and nuclear p-IKKα T23 in castration-naïve PC
- Low
- High
- HR 0.9 95% CI 0.4-2.2 log-rank p=0.80

(C) Kaplan Meier curves showing associations of nuclear p-IKKα T23 and TTDR in patients with high Ki67.

Number of patients at risk:
- Low: 11(0) 3(3) 0(3) 0(3) 0(3)
- High: 17(0) 6(0) 1(1) 0(1) 0(1) 0(1)

FIGURE 3 Nuclear p-IKKα T23 is associated with good prognosis in CRPC patients with low Ki67. A, Kaplan Meier curves showing associations of nuclear p-IKKα T23 and time to death from relapse (TTDR) in the full cohort. B, Kaplan Meier curves showing associations of nuclear p-IKKα T23 and TTDR in patients with low Ki67. C, Kaplan Meier curves showing associations of nuclear p-IKKα T23 and TTDR in patients with high Ki67. CI, confidence interval; CRPC, castration-resistant prostate cancer; HR, hazards ratio; IKK, inhibitory κ-B kinase; IKKα, IKK subunits α.
**Table 4** Correlations (P value) between the expression of total IKKα, p-IKKα S180, p-IKKα T23, NEMO, total IKKβ, p-AKT S473 and androgen receptor in the cytoplasm and the nucleus of prostate cancer cells during the transition from hormone-naïve to castration-resistant prostate cancer (n = 115)

| Hormone-naïve prostate cancer | Castration-resistant prostate cancer |
|-------------------------------|------------------------------------|
|                               | IKKα                               | p-IKKα S180 | p-IKKα T23 |
|                               | Cytoplasmic | Nuclear   | Cytoplasmic | Nuclear   | Cytoplasmic | Nuclear |
| Canonical NF-κβ pathway       | cNEMO          | 0.22      | 0.48      | 0.20      | 0.64      | 0.06      | 0.57      |
|                               | nNEMO          | 0.33      | 0.04*     | 0.63      | 0.31      | 0.32      | 0.87      |
|                               | dIKKβ          | 0.36      | 0.42      | 0.35      | 0.07      | 0.61      | 0.19      |
|                               | nIKKβ          | 0.60      | 0.96      | 0.20      | 0.23      | 0.27      | 0.29      |
| Akt pathway                   | m p-Akt S473   | 0.43      | 0.28      | 0.82      | 0.07      | 0.59      | 0.18      |
|                               | c p-Akt S473   | 0.09      | 0.80      | 0.94      | 0.45      | 0.13      | 0.42      |
|                               | n p-Akt S473   | 0.17      | 0.58      | 0.74      | 0.39      | 0.87      | 0.65      |
| Androgen receptor pathway     | nAR            | 0.16      | 0.88      | 0.09      | 0.76      | 0.30      | 0.02*     |
|                               |                |           |           |           |           |           |           |

Abbreviations: IKK, inhibitory κ-B kinase; IKKβ, IKK subunit β; NEMO, NF-κβ essential modulator; NF-κβ, nuclear factor κβ; m/c/n, membrane/cyttoplasm/nuclear.

*P < .05; **P < .01; ***P < .001.

Many studies associate IKKα with PC cell proliferation, survival, inflammation features and IKKβ associates with PC cell proliferation, survival, invasion, angiogenesis, independent growth, and tumor metastasis, suggesting IKKα inhibitors as potential therapeutic agents to treat localized and advanced PC. However, differences in IKKα expression, localization and AR inhibition before and after castration suggest the role between HNPC and CRPC are unclear. For this reason, we should establish prognostic markers able to differentiate which treatment this is the first study to investigate this concept by determining the prognostic role between HNPC and CRPC (Table 4). As IKKα was not associated with prognosis in the total cohort in HNPC, we only conducted the analysis for CRPC patients. Under univariate analysis, PSA (p = 0.02), Ki67 (p = 0.01), total nuclear IKKα (p = 0.01), and IKKβ S180 (p = 0.01) were independent prognostic factors. Under multivariate analysis, total nuclear IKKα (p = 0.03) trended towards significance, and AR association with inflammatory features and IKKα expression on patients’ survival. We performed a univariate and multivariate cox regression analysis to determine the effect of clinicopathological parameters, in inflammatory features and IKKα expression on patients’ survival (Table 3). As IKKα was not associated with prognosis in the total cohort in HNPC, we only conducted the analysis for CRPC patients. Under univariate analysis, PSA (p = 0.02), Ki67 (p = 0.01), total nuclear IKKα (p = 0.01), and IKKβ S180 (p = 0.01) were independent prognostic factors. Total nuclear IKKα and nuclear p-Akt S473, respectively (p = 0.03 for both markers) are correlated with IKKα (canonical NF-κB pathway) and p-IKKα T23 were strongly correlated with the expression of total IKKα and total IKKα S180 (noncanonical NF-κB pathway), and p-IKKα T23 were strongly correlated with the expression of total IKKα and total IKKα S180 (noncanonical NF-κB pathway).
infiltrate and whether it is acting via the canonical or noncanonical NF-κB pathway.

Assessing the role of IKKα is complex, given its different biological functions that are dependent on both cellular type and localization. Although the activity of cytoplasmic IKKα is associated with the activation of NF-κB pathways (canonical and noncanonical), nuclear IKKα has consistently been demonstrated to work independently in PC. Furthermore, IKKα is a substrate for multiple kinases that phosphorylate it at specific residues. For example, the phosphorylation of IKKα at S180 is known to take place in the cytoplasm by NIK, a prerequisite for activating the noncanonical NF-κB pathway, whereas phosphorylation at T23 is by Akt.

### FIGURE 4

IKKα crosstalk with other members of cancer pathways in the cytoplasm and the nucleus of prostate cancer cells during the transition from hormone-naïve to castration-resistant prostate cancer. A, IKKα crosstalk in hormone-naïve prostate cancer. Total nuclear IKKα correlates with nuclear factor-κB (NF-κB) essential modulator (NEMO), and nuclear phosphorylated IKKα at threonine 23 correlates with nuclear androgen receptor. B, Crosstalk in castration-resistant prostate cancer. Phosphorylated IKKα at serine 180 (noncanonical NF-κB pathway) and phosphorylated IKKα at threonine 23 correlate with IKKβ (canonical NF-κB pathway) in the cytoplasm. In addition, phosphorylated IKKα at threonine 23 correlates with phosphorylated Akt at serine 473 (Akt pathway) in the cytoplasm. Finally, there is a correlation between IKKα and IKKβ in the nucleus. IKK, inhibitory κ-B kinase; IKKα, IKK subunits α; IKKβ, IKK subunits β.

### TABLE 5

Analysis of the effect of clinicopathological parameters, inflammatory features, and IKKα on the survival of castration-resistant prostate cancer (n = 115)

| Clinicopathological parameters | Castration-resistant prostate cancer | Time to death from recurrence | Univariate HR (95% CI) | P | Multivariate HR (95% CI) | P |
|-------------------------------|------------------------------------|------------------------------|------------------------|---|--------------------------|---|
| Age (≤70/>70 y)                |                                    |                              | 1.47 (0.90-2.39)       | .12 | ...                      | ... |
| Gleason score (<7/>7)         |                                    |                              | 1.16 (0.69-1.96)       | .57 | ...                      | ... |
| PSA (≤10 ng/mL/>10 ng/mL)     |                                    |                              | 2.22 (1.14-4.33)       | .02* | 3.00 (1.02-8.81)         | .05 |
| Ki67 (≤1% cells/>1% cells)    |                                    |                              | 2.60 (1.30-5.20)       | .01** | 2.40 (0.75-7.66)         | .14 |
| Inflammatory features (low/high) |                                |                              |                        |    |                          |    |
| CD68+ macrophages             |                                    |                              | 0.34 (0.06-1.88)       | .22 | ...                      | ... |
| CD8+ T-cells                  |                                    |                              | 1.73 (0.40-7.44)       | .46 | ...                      | ... |
| CD3+ T-cells                  |                                    |                              | 3.46 (0.73-16.40)      | .12 | ...                      | ... |
| FOXP3+ T-cells                |                                    |                              | 0.89 (0.24-3.38)       | .87 | ...                      | ... |
| IKKα pathway (low/high)       |                                    |                              |                        |    |                          |    |
| c IKKα                        |                                    |                              | 1.65 (0.90-3.02)       | .11 | ...                      | ... |
| n IKKα                        |                                    |                              | 2.60 (1.27-5.33)       | .01* | 2.50 (0.81-7.73)         | .11 |
| c p-IKKα S180                 |                                    |                              | 2.10 (1.17-3.76)       | .01** | 1.68 (0.69-4.13)         | .26 |
| n p-IKKα S180                 |                                    |                              | 1.22 (0.67-2.20)       | .51 | ...                      | ... |
| c p-IKKα T23                  |                                    |                              | 1.06 (0.59-1.88)       | .86 | ...                      | ... |
| n p-IKKα T23                  |                                    |                              | 1.10 (0.62-1.96)       | .75 | ...                      | ... |

Abbreviations: CI, confidence interval; c/n, citoplasmic/nuclear; HR, hazards ratio; IKK, inhibitory κ-B kinase; IKKβ, IKK subunit β; NEMO, NF-κB essential modulator; NF-κB, nuclear factor κB; m/c/n, membrane/citoplasmic/nuclear; PSA, prostate-specific antigen.

*P < .05; **P ≤ .01.
functionality and make deconvolution of its roles as instigator and/or responder challenging in an oncogenic setting.36 Several IKKα-related interactions drive PC progression, such as the crosstalk between the canonical and noncanonical NF-κB pathways, and more importantly, the positive relationship between noncanonical NF-κB and AR signaling.29 However, how this differs between HNPC and CRPC is not well understood. To help address this question, this study utilized patients able to provide both HNPC and CRPC samples to assess the differences between the two in the same cohort. The results showed that cytoplasmic IKKα was associated with low AR in HNPC, where patients presenting high levels of total cytoplasmic IKKα and low AR protein expression had longer CSS compared with patients expressing low total cytoplasmic IKKα. Furthermore, low total cytoplasmic IKKα-expressing patients with high AR tended to live longer than those with high levels of total cytoplasmic IKKα, indicating that IKKα inhibitors could potentially be of benefit to the latter group. Additionally, we found that the high expression of nuclear IKKα and cytoplasmic p-IKKα S180 was associated with shorter TTDR in patients with CRPC but was not independently prognostic. Furthermore, p-IKKα S180 (noncanonical NF-κB pathway) was correlated with IKKβα (canonical NF-κB pathway) in the cytoplasm of patient with CRPC samples, suggesting interactions between the canonical and noncanonical pathways. Moreover, cytoplasmic total IKKα correlated with cytoplasmic IKKβ, indicating that a proportion of the total IKKα accumulated in the cytoplasm may be involved with the IKKβα/NEMO complex, which activates the canonical NF-κB pathway.27 This is not surprising as IKKα is a critical component of both pathways and suggests that it is acting to drive poor prognosis via the canonical NF-κB pathway in CRPC, both directly via the IKK complex and indirectly through crosstalk with the noncanonical NF-κB pathway.

Despite several studies having demonstrated the involvement of nuclear IKKα in PC progression and metastasis, little is known about the mechanistic connection between prostate tumorigenesis and nuclear IKKα activity.19,21,22,33 We found nuclear IKKα correlated with nuclear NEMO in HNPC, which supports Margalef’s report of a complex comprised of the active isoform of nuclear IKKα (p45-IKKα) and nuclear NEMO to prevent apoptosis and sustain tumor growth, although this study was in colorectal cancer.38 In addition, nuclear IKKα correlated with nuclear IKKβ in CRPC to drive bad prognosis, suggesting their crosstalk is through alternative pathways (independent from NF-κB pathway). Although IKKα can be distributed in the cytoplasm as well as in the nucleus, IKKβ is mainly located in the cytoplasm, although it has also been found to have a nuclear function that is related to DNA repair.39

Despite the interaction between nuclear IKKα and AR being already known,30 this is the first study demonstrating a positive correlation between the expression of nuclear p-IKKα T23 and AR in HNPC, suggesting crosstalk between these proteins. In addition, IKKα phosphorylation at T23 by Akt has been described as crucial for its translocation into the nucleus15 and the correlation we found between p-IKKα T23 and Akt in CRPC supports this interaction, which is consistent with the study by Luo et al who demonstrated that nuclear IKKα accumulation correlated with the progression and the clinical grade of PC.21 Interestingly, we observed no correlation between p-IKKα T23 and Akt in HNPC, suggesting T23 phosphorylation of IKKα may involve another kinase in this phase of the disease.

Interestingly, these results also suggest an involvement of p-IKKα T23 in the canonical NF-κB pathway, with cytoplasmic p-IKKα T23 correlating with IKKβ in the cytoplasm and the nucleus in patients with CRPC. This is the first study to propose an interaction between p-IKKα T23 and IKKβ, potentially via an independent mechanism, but this requires further investigation.

The activity of IKKα is known to be dependent on molecular and cellular changes in the tumor microenvironment, including those promoted by therapeutic interventions. The inflammatory response elicited by androgen deprivation promotes the deregulation of several pathways including NF-κB and is a major contributor to the emergence of androgen-independent PC.27,41,43 Despite most of the studies analyzing macrophages (CD68+) and lymphocytes (CD3+ and CD8+) in PC tissues identifying them being protumorigenic,34 their prognostic relevance is unclear in PC. Therefore, we evaluated the association between specific immune cells and IKKα expression during the transition from HNPC to CRPC. The results showed high expression of cytoplasmic p-IKKα T23 associated with high CD3+ and CD8+ tumor-infiltrated lymphocytes (TILs) in HNPC. On the other hand, high cytoplasmic p-IKKα T23 was associated with low CD3+ TILs and high macrophage (CD68+) infiltration in CRPC, suggesting the involvement of macrophages (CD68+) in CRPC progression. Accordingly, macrophage infiltration induced by castration5,46 has been related with the acquisition of CRPC.47

Despite IKKα being seen as a key mediator of inflammation and metastasis in PC, its relationship with cell proliferation remains unclear. In this study, we showed that high p-IKKα T23 nuclear expression was significantly associated with low Ki67 in CRPC and allied with better prognosis, suggesting that it is not related to proliferation in PC.

5 | CONCLUSION

In conclusion, we have shown that total cytoplasmic IKKα is potentially a marker for good prognosis for HNPC patients with low AR expression, and it does not associate with members from the canonical NF-κB pathway. Furthermore, IKKα is a marker for poor prognosis for patients with CRPC, with nuclear IKKα and cytoplasmic p-IKKα S180 associating with shorter TTDR. Cytoplasmic p-IKKα S180 also correlate with cytoplasmic IKKβ to drive bad prognosis. These results suggest that the noncanonical NF-κB pathway is dampened by the canonical pathway to promote disease progression. Taken together, these data indicate that patients with CRPC may benefit from treatment with IKKα inhibitors if they were to be developed as therapeutic agents. We note that any expression of IKKα can be used as an independent prognostic marker, and more studies will be necessary to further validate and establish whether combining...
IKKα with other markers, such as AR could be used as prognostic biomarkers.

ACKNOWLEDGMENTS

The author would like to thank McAllister Milly J, McCall Pammela, and Hatzieriema Sophia, whose investigation provided much of the experimental data analyzed in this study. The author also thank Underwood M, who supplied us with clinical specimens. And, last but not least, gratitude to MacKenzie Lewis, Roseweir Antonio, Marie Boyd, Paul Andrew, Edwards Joanne, and MacKay Simon for their expertise and assistance throughout all aspects of this study. The author thank Prostate Cancer UK (S14-003) to the University of Glasgow, and grant PG12-27 to the University of Strathclyde.

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.

ORCID

Melania Montes http://orcid.org/0000-0002-4268-6608

REFERENCES

1. Shukla ME, Yu C, Reddy CA, et al. Evaluation of the current prostate cancer staging system based on cancer-specific mortality in the surveillance, epidemiology, and end results database. Clin Genitourin Cancer. 2015;13(1):17-21. https://doi.org/10.1016/j.clgc.2014.07.003
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. 2014. CA Cancer J Clin. 2014;64(1):9-29. https://doi.org/10.3322/caac.21208
3. Crawford ED, Ventii K, Shore ND. New biomarkers in prostate cancer. Oncol Williston Park N. 2014;28(2):135-142.
4. Drake R. Prostate cancer. Novel technique for early detection of lymph node metastases. Nat Rev Urol. 2010;7(9):475. https://doi.org/10.1038/nruro.2010.130
5. Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009;6(2):76-85. https://doi.org/10.1038/ncpunr.1296
6. Marques RB, Dits NF, Erkens-Schulze S, van Weerden WM, Jenster G. Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models. PLoS One. 2010;5(10):e13500. https://doi.org/10.1371/journal.pone.0013500
7. Ramalingam S, Ramamurthy VP, Njar VCO. Dissecting major signaling pathways in prostate cancer development and progression: mechanisms and novel therapeutic targets. J Steroid Biochem Mol Biol. 2017;166:16-27. https://doi.org/10.1016/j.jsbmb.2016.07.006
8. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-xB as the matchmaker. Nat Immunol. 2011;12(8):715-723. https://doi.org/10.1038/ni.2060
9. Kendellen MF, Bradford JW, Lawrence CL, Clark KS, Baldwin AS. Canonical and non-canonical NF-xB signaling promotes breast cancer tumor-initiating cells. Oncogene. 2014;33(10):1297-1305. https://doi.org/10.1038/onc.2013.64
10. Shih VF-S, Tsui R, Caldwell A, Hoffmann A. A single NF-xB system for both canonical and non-canonical signaling. Cell Res. 2011;21(1):86-102. https://doi.org/10.1038/cr.2010.161
11. Lessard L, Bègin LR, Gleave ME, Mes-Masson A-M, Saad F. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer. 2005;93(9):1019-1023. https://doi.org/10.1038/sj.bjc.6602796
12. Lessard L, Saad F, Le Page C, et al. NF-kappaB2 processing and p52 nuclear accumulation after androgenic stimulation of LNCaP prostate cancer cells. Cell Signal. 2007;19(5):1093-1100. https://doi.org/10.1016/j.cellsig.2006.12.012
13. Nadiminty N, Chun JY, Lou W, Lin X, Gao AC. NF-kappaB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation. Prostate. 2008;68(16):1725-1733. https://doi.org/10.1002/pros.20839
14. Nadiminty N, Lou W, Sun M, et al. Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. Cancer Res. 2010; 70(8):3309-3319. https://doi.org/10.1158/0008-5472.CAN-09-3703
15. Nadiminty N, Dutt S, Tepper C, Gao AC. Microarray analysis reveals potential target genes of NF-kappaB2/p52 in LNCaP prostate cancer cells. Prostate. 2010;70(3):276-287. https://doi.org/10.1002/pros.21062
16. Nadiminty N, Tummala R, Liu C, et al. NF-xB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther. 2013;12(8):1629-1637. https://doi.org/10.1158/1535-7163.MCT-13-0027
17. Nadiminty N, Tummala R, Liu C, Lou W, Evans CP, Gao AC. NF-xB2/p52-c-Myc/nRNPA1 pathway regulates expression of androgen receptor splice variants and enzalutamide sensitivity in prostate cancer. Mol Cancer Ther. 2015;14(8):1884-1895. https://doi.org/10.1158/1535-7163.MCT-14-1057
18. Paul A, Edwards J, Pepper C, Mackay S. Inhibitory-xB kinase (IKK) α and nuclear factor-xB (NFxB)-inducing kinase (NIK) as anti-cancer drug targets. Cells. 2018;7(10), https://doi.org/10.3390/cells7100176
19. Mahato R, Qin B, Cheng K. Blocking IKKα expression inhibits prostate cancer invasiveness. Pharm Res. 2011;28(6):1357-1369. https://doi.org/10.1007/s11095-010-0351-z
20. Shukla S, Kanwal R, Shankar E, et al. Apigenin blocks IKKα activation and suppresses prostate cancer progression. Oncotarget. 2015;6(31):31216-31222. https://doi.org/10.18632/oncotarget.5157
21. Luo J-L, Tan W, Ricono JM, et al. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature. 2007;446(7136):690-694. https://doi.org/10.1038/nature05656
22. Cao Y, Luo J-L, Karin M. IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells. Proc Natl Acad Sci USA. 2007;104(10):15852-15857. https://doi.org/10.1073/pnas.0707628104
23. Anthony NG, Baiter J, Berretta G, et al. Inhibitory kappa B kinase α (IKKα) inhibitors that recapitulate their selectivity in cells against isofom-related biomarkers. J Med Chem. 2017;60(16):7043-7066. https://doi.org/10.1021/acs.jmedchem.7b00484
24. Bennett L, Quinn J, McCall P, et al. High IKKα expression is associated with reduced time to recurrence and cancer specific survival in oesogroen cancer (ER)-positive breast cancer. Int J Cancer. 2017;140(7):1633-1644. https://doi.org/10.1002/ijc.30578
25. Kirkegaard T, Edwards J, Tovey S, et al. Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology. 2006;48(7):787-794. https://doi.org/10.1111/j.1365-2559.2006.02412.x
26. Fisher G, Yang ZH, Kudahetti S, et al. Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort. Br J Cancer. 2013;108(2):271-277. https://doi.org/10.1038/bjc.2012.598
27. Nguyen DP, Li J, Yadav SS, Tewari AK. Recent insights into NF-xB signalling pathways and the link between inflammation and prostate cancer. BJU Int. 2014;114(2):168-176. https://doi.org/10.1111/bju.12488
28. Ammirante M, Luo J-L, Grivennikov S, Nedospasov S, Karin M. B-cell-derived lymphotixin promotes castration-resistant prostate cancer. Nature. 2010;464(7286):302-305. https://doi.org/10.1038/nature08782
29. Tegowski M, Baldwin A. Noncanonical NF-xB in cancer. Biomedicines. 2018;6(2), https://doi.org/10.3390/biomedicines6020066
30. Khurana N, Sikka SC. Targeting crosstalk between Nrf-2, NF-xB and androgen receptor signaling in prostate cancer. Cancers. 2018;10(10), https://doi.org/10.3390/cancers10100352
31. Shankar E, Weis MC, Avva J, et al. Complex systems biology approach in connecting PI3K-Akt and NF-κB pathways in prostate cancer. Cells. 2019;8(3), https://doi.org/10.3390/cells8030201
32. Huang W-C, Hung M-C. Beyond NF-κB activation: nuclear functions of IκB kinase α. J Biomed Sci. 2013;20:3. https://doi.org/10.1186/1423-0127-20-3
33. Ammirante M, De Laurenzi V, Graziano V, Turco MC, Rosati A. BAG3 is required for IKKα nuclear translocation and emergence of castration-resistant prostate cancer. Cell Death Dis. 2011;2:e139. https://doi.org/10.1038/cddis.2011.23
34. Kwak YT, Guo J, Shen J, Gaynor RB. Analysis of domains in the IKKα and IKKβ proteins that regulate their kinase activity. J Biol Chem. 2000;275(19):14752-14759. https://doi.org/10.1074/jbc.m001039200
35. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 1999;401(6748):82-85. https://doi.org/10.1038/43466
36. Hinz M, Scheidereit C. The IκB kinase complex in NF-κB regulation and beyond. EMBO Rep. 2014;15(1):46-61. https://doi.org/10.1002/embr.201337983
37. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008;132(3):344-362. https://doi.org/10.1016/j.cell.2008.01.020
38. Margalef P, Fernández-Majada V, Villanueva A, et al. A truncated form of IKKα is responsible for specific nuclear IKK activity in colorectal cancer. Cell Rep. 2012;2(4):840-854. https://doi.org/10.1016/j.celrep.2012.08.028
39. Sakamoto K, Hikiya Y, Nakagawa H, et al. Promotion of DNA repair by nuclear IKKβ phosphorylation of ATM in response to genotoxic stimuli. Oncogene. 2013;32(14):1854-1862. https://doi.org/10.1038/onc.2012.192
40. Jain G, Voogdt C, Tobias A, et al. IκB kinases modulate the activity of the androgen receptor in prostate carcinoma cell lines. Neoplasia Y N. 2012;14(3):178-189. https://doi.org/10.1593/neo.111444
41. Vitkin N, Nersesian S, Siemens DR, Koti M. The tumor immune contexture of prostate cancer. Front Immunol. 2019;10:603. https://doi.org/10.3389/fimmu.2019.00603
42. Austin DC, Strand DW, Love HL, et al. NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer SARI resistance. Prostate. 2016;76(11):1004-1018. https://doi.org/10.1002/pros.23195
43. Shiao SL, Chu GC-Y, Chung LWK. Regulation of prostate cancer progression by the tumor microenvironment. Cancer Lett. 2016;380(1):340-348. https://doi.org/10.1016/j.canlet.2015.12.022
44. Strasner A, Karin M. Immune infiltration and prostate cancer. Front Oncol. 2015;5:128. https://doi.org/10.3389/fonc.2015.00128
45. Silva JAF, Bruni-Cardoso A, Augusto TM, et al. Macrophage roles in the clearance of apoptotic cells and control of inflammation in the prostate gland after castration. Prostate. 2018;78(2):95-103. https://doi.org/10.1002/pros.23449
46. Gannon PO, Poisson AO, Delvoye N, Lapointe R, Mes-Masson A-M, Saad F. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods. 2009;348(1-2):9-17. https://doi.org/10.1016/j.jim.2009.06.004
47. Calcinozzo A, Spataro C, Zagato E, et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature. 2018;559(7714):363-369. https://doi.org/10.1038/s41586-018-0266-0
48. Nonomura N, Takayama H, Nakayama M, et al. Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer. BJU Int. 2011;107(12):1918-1922. https://doi.org/10.1111/j.1464-410X.2010.09804.x

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Montes M, MacKenzie L, McAllister MJ, et al. Determining the prognostic significance of IKKα in prostate cancer. The Prostate. 2020;80:1188-1202. https://doi.org/10.1002/pros.24045